Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework
Published inNeurobiology of aging, vol. 52, p. 214-227
Publication date2017
Abstract
Citation (ISO format)
CHIOTIS, Konstantinos et al. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. In: Neurobiology of aging, 2017, vol. 52, p. 214–227. doi: 10.1016/j.neurobiolaging.2016.07.012
Main files (1)
Article (Published version)
Identifiers
- PID : unige:94309
- DOI : 10.1016/j.neurobiolaging.2016.07.012
- PMID : 28317650
Journal ISSN0197-4580